SPRY Stock Overview
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ARS Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.26 |
| 52 Week High | US$11.27 |
| 52 Week Low | US$2.55 |
| Beta | 0 |
| 1 Month Change | -9.53% |
| 3 Month Change | 26.69% |
| 1 Year Change | 27.86% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 36.30% |
Recent News & Updates
Shareholder Returns
| SPRY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.8% | 1.0% | 1.2% |
| 1Y | 27.9% | 0.7% | 24.9% |
Return vs Industry: SPRY exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: SPRY exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| SPRY volatility | |
|---|---|
| SPRY Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SPRY's share price has been volatile over the past 3 months.
Volatility Over Time: SPRY's weekly volatility has decreased from 16% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 25 | Rich Lowenthal | ars-pharma.com |
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
ARS Pharmaceuticals, Inc. Fundamentals Summary
| SPRY fundamental statistics | |
|---|---|
| Market cap | US$820.26m |
| Earnings (TTM) | -US$54.36m |
| Revenue (TTM) | US$30.00k |
Over9,999x
P/S Ratio-14.7x
P/E RatioIs SPRY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPRY income statement (TTM) | |
|---|---|
| Revenue | US$30.00k |
| Cost of Revenue | US$20.07m |
| Gross Profit | -US$20.04m |
| Other Expenses | US$34.33m |
| Earnings | -US$54.36m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.56 |
| Gross Margin | -66,786.67% |
| Net Profit Margin | -181,216.67% |
| Debt/Equity Ratio | 0% |
How did SPRY perform over the long term?
See historical performance and comparison